Danner, Bernhard

[["dc.bibliographiccitation.firstpage","286"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","293"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Korte, Kerstin Pia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Danner, Bernhard"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2021-06-01T10:48:55Z"],["dc.date.available","2021-06-01T10:48:55Z"],["dc.date.issued","2017"],["dc.description.abstract","AIMS: The objective of this study was to examine the impact of guideline-defined subtypes of severe aortic stenosis (AS) on long-term outcomes after TAVI. METHODS AND RESULTS: Four hundred (400) consecutive patients who underwent TAVI (203 transapical, 197 transfemoral) at our institution 8/2008-3/2013 were followed systematically (for up to seven years). One hundred and forty-seven (147) individuals suffered from NEF-HG AS (LV-EF ≥50%, high Pmean ≥40 mmHg), 63 from LEF-HG AS (LV-EF <50%, high gradient), 77 from PLF-LG AS (LV-EF ≥50%, low gradient, stroke volume index [SVI] <35 ml/m²), and 81 from LEF-LG AS (LV-EF <50%, low gradient). LEF-LG status was associated with the highest all-cause and cardiovascular mortality and MACCE rate, whereas NEF-HG patients exhibited the best outcome (i.e., median survival 5.1 years in NEF-HG vs. 1.3 years in LEF-LG, p=0.0006; or vs. 3.3 years in PLF-LG, p=0.02). In multivariate analysis, LEF-LG status emerged as the outcome predictor with the highest hazard ratio for all-cause mortality (HR 2.86, p=0.003), cardiovascular mortality (HR 6.53, p<0.0001), and MACCE (HR 2.44, p=0.007), whereas neither baseline EF nor SVI <35 ml/m² independently predicted these endpoints. CONCLUSIONS: These findings suggest that an assessment of LV-EF alone for outcome prediction after TAVI is inadequate; it is the guideline-defined subtype of AS that determines outcome."],["dc.identifier.doi","10.4244/EIJ-D-16-00801"],["dc.identifier.gro","3142338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86102"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.issn","1774-024X"],["dc.title","Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","270"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Arnemann, Johanna"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2019-01-29T11:57:51Z"],["dc.date.available","2019-01-29T11:57:51Z"],["dc.date.issued","2017"],["dc.description.abstract","ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3 expression may have a negative prognostic impact in patients with NSCLC."],["dc.identifier.doi","10.1159/000477619"],["dc.identifier.pmid","28683465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57421"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","final"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0232"],["dc.relation.issn","0030-2414"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","362"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hupfeld, Timo"],["dc.contributor.author","Krause, Doris"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Guedenzoph, Bjoern"],["dc.contributor.author","Aung, Thiha"],["dc.contributor.author","Inagaki, Nobuya"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:29:56Z"],["dc.date.available","2018-11-07T09:29:56Z"],["dc.date.issued","2013"],["dc.description.abstract","Patients with advanced-stage bronchial cancer benefit from systemic cytostatic therapy, in particular from regimens integrating cisplatin and taxanes. However, eventual disease progression leads to a fatal outcome in most cases, originating from tumor cells resisting chemotherapy. We here show that the intracellular ATP-binding cassette transporter A3 (ABCA3), previously recognized as critical for the secretion of surfactant components from type 2 pneumocytes, is expressed in non-small-cell lung cancer (NSCLC) cells. With some heterogeneity in a given specimen, expression levels detected immunohistochemically in primary cancer tissue were highest in adenocarcinomas and lowest in small cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges as a modulator of NSCLC cell susceptibility to cytostatic therapy. Copyright (c) 2013 S. Karger AG, Basel"],["dc.description.sponsorship","Faculty of Medicine, Georg August University Gottingen, Germany"],["dc.identifier.doi","10.1159/000348884"],["dc.identifier.isi","000320219100007"],["dc.identifier.pmid","23689165"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31175"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0030-2414"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","553"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","563"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Viel, Tanja"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Teucher, Nils"],["dc.contributor.author","Hanekop, Gunnar"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Seipelt, Ralf G."],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2017-09-07T11:48:50Z"],["dc.date.available","2017-09-07T11:48:50Z"],["dc.date.issued","2012"],["dc.description.abstract","Transcatheter aortic valve implantation (TAVI) has recently developed into an acceptable alternative to conventional surgery in high-risk patients. However, information on the identification of patients gaining most benefit from this procedure is still limited. The aim of this study was to evaluate safety and efficacy of TAVI in different patient cohorts. Between August 2008 and December 2010, 180 high-risk patients underwent TAVI at our institution (97 transapical and 83 transfemoral approaches). Periprocedural complications as well as mortality and incidence of MACCE during follow-up were recorded. Mean age was 82 +/- A 5 years, and mean logistic EuroScore 27 +/- A 14%. In the total cohort, 30-day mortality was 8.9% and 12-month survival (according to Kaplan-Meier-analysis) 72%, with no significant differences between the two approaches. However, a significant difference in survival was obvious after stratification of patients according to logistic EuroScore mortality estimates. Survival proportions at 1 year were 62% in patients with logistic EuroScore > 40%, 71% in patients with EuroScore 20-40% and 80% in octogenarians with EuroScore < 20% (P = 0.009). Furthermore, the observed median event-free survival as an indicator for morbidity ranged between 315 days in the first, 442 days in the second and 710 days in the third group (P = 0.1). TAVI proved to be feasible with reproducible results. However, mortality and rehospitalization rates were considerably high in specific patient cohorts, suggesting that the risk-to-benefit ratio of TAVI should be validated individually. In the present study, octogenarians with logistic EuroScore < 20% could be identified as candidates apparently gaining high benefit from the procedure."],["dc.identifier.doi","10.1007/s00392-012-0426-4"],["dc.identifier.gro","3142507"],["dc.identifier.isi","000305397200006"],["dc.identifier.pmid","22350751"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8091"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8866"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Edwards Lifesciences"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The risk-to-benefit ratio of transcatheter aortic valve implantation in specific patient cohorts: a single-centre experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Henric-Petri, Hannah"],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Strecker, Jasmin"],["dc.contributor.author","Holland, Rainer"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Corso, Jasmin"],["dc.contributor.author","Wagner, Sebastian"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Danner, Bernd"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Serve, Hubert"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Oellerich, Thomas"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1158/1538-7445.AM2014-2487"],["dc.identifier.isi","000349906903219"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32050"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","105th Annual Meeting of the American-Association-for-Cancer-Research (AACR)"],["dc.relation.eventlocation","San Diego, CA"],["dc.relation.issn","1538-7445"],["dc.relation.issn","0008-5472"],["dc.title","Comprehensive quantitative proteomic profiling of lung cancers reveals novel biomarkers and potential drug targets"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E174"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","The Heart Surgery Forum"],["dc.bibliographiccitation.lastpage","E177"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Tirilomis, Theodor"],["dc.contributor.author","Bougioukas, Ioannis G."],["dc.contributor.author","Friedrich, Martin G."],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Schoendube, Friedrich A."],["dc.date.accessioned","2020-12-10T18:42:40Z"],["dc.date.available","2020-12-10T18:42:40Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1532/hsf.2893"],["dc.identifier.eissn","1522-6662"],["dc.identifier.issn","1098-3511"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17343"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78041"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Re-exploration Early after Cardiac Surgery in Adults: The Importance of Bleeding-Related Complications"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","482"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Interactive Cardiovascular and Thoracic Surgery"],["dc.bibliographiccitation.lastpage","488"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Andrasi, Terezia B."],["dc.contributor.author","Kekesi, Violetta"],["dc.contributor.author","Merkely, Bela"],["dc.contributor.author","Grossmann, Marius"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.date.accessioned","2018-11-07T10:25:09Z"],["dc.date.available","2018-11-07T10:25:09Z"],["dc.date.issued","2017"],["dc.description.abstract","OBJECTIVES: We aimed to develop a simple, reliable, and timesaving technique for the therapy of thoracoabdominal aortic (TAA) aneurysms that are not suitable for endovascular repair. METHODS: In this pilot study, we sought to combine the advantages of classic open vascular procedure with the use of endoscopic surgical tools and small skin incisions to develop a minimally invasive approach for TAA replacement. The following procedures were used: endoscopic exposure and closure of the lower intercostal arteries; small posterolateral thoracotomy and left retroperitoneal incisions to expose the anastomotic regions of the aorta; partial anticoagulation; passive bypass and sequential aortic clamping; tunnelling of the graft through the native aortic lumen (endoaneurysmorrhaphy) and open performance of vascular anastomosis. RESULTS: Five mixed-breed dogs (25-35 kg) underwent minimally invasive TAA replacement. All animals survived the operation without blood transfusion (lowest Hb = 5.5 mg/dl). Total operation time was 364 +/- 46.3 min. Clamping times were 17.6 +/- 3.2 min for proximal anastomosis, 33.2 +/- 2.48 min for visceral patch and 11 +/- 2.3 min for distal anastomosis. The pull-through procedure of graft through the native aorta was performed during the visceral clamp time. CONCLUSIONS: Surgical replacement of the TAA through small transverse incisions of the thoracic and abdominal wall is feasible and allows open performance of all vascular anastomosis with no leakage at any anastomotic site. Further experimental studies and clinical implementation are needed to establish the safety and long-term outcome of minimally invasive TAA replacement as a possible primary therapeutic tool for complex aneurysms that are not suitable for endovascular treatment and require open surgical repair."],["dc.description.sponsorship","European Society of Vascular Surgery"],["dc.identifier.doi","10.1093/icvts/ivw379"],["dc.identifier.isi","000404043800002"],["dc.identifier.pmid","28040750"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42797"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1569-9285"],["dc.relation.issn","1569-9293"],["dc.title","A minimally invasive approach for open surgical thoracoabdominal aortic replacement: experimental concept for a novel surgical procedure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1841"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Annals of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","1843"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Jebran, Ahmad Fawad"],["dc.contributor.author","Schmidt, Karsten"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Schoendube, Friedrich A."],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2017-09-07T11:45:25Z"],["dc.date.available","2017-09-07T11:45:25Z"],["dc.date.issued","2014"],["dc.description.abstract","This clinical report deals with a giant true pulmonary venous aneurysm, which was partially thrombosed. The overall incidence of pulmonary venous aneurysms is unknown, and they are reported only occasionally. We present the case of a previously healthy man with acute onset of ischemic cerebral stroke. The cause was a thrombus in a huge aneurysm of the left superior pulmonary vein. The patient subsequently underwent uncomplicated therapy for stroke, including thrombolysis followed by excision of the giant pulmonary venous aneurysm. As curative therapy we recommend complete resection of this rare entity. (C) 2014 by The Society of Thoracic Surgeons"],["dc.identifier.doi","10.1016/j.athoracsur.2013.12.087"],["dc.identifier.gro","3142027"],["dc.identifier.isi","000344746600085"],["dc.identifier.pmid","25441803"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3734"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.eissn","1552-6259"],["dc.relation.issn","0003-4975"],["dc.title","Aneurysm of the Pulmonary Vein: An Unusual Cause of Stroke"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1038"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The Annals of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","1043"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Hellms, Timo"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Didilis, Vassilios N."],["dc.contributor.author","Fuezesi, Laszlo"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.date.accessioned","2018-11-07T08:52:41Z"],["dc.date.available","2018-11-07T08:52:41Z"],["dc.date.issued","2011"],["dc.description.abstract","Background. Non-small cell lung cancer (NSCLC) is one of the most aggressive tumors, with a very low overall survival rate. We investigated surgically resected squamous cell carcinoma (SCC) and adenocarcinoma (AC) to identify chromosomal imbalances and their value for individual prognostication. Methods. A total of 80 cases, including 55 SCC and 25 AC, were retrospectively analyzed by comparative genomic hybridization. To model the sequential cytogenetic events, an oncogenetic tree model was applied based on maximum likelihood estimation. Clinicopathologic data and follow-up data were correlated with chromosomal imbalances. Results. Fifty-one percent of patients were in stage I, 32% in stage II, and 17% in stage III, without statistically significant differences in staging distribution between SCC and AC. The average number of copy number imbalances was higher in SCC than in AC (9.4 +/- 1.2 vs 5.4 +/- 1.1; p = 0.11). Frequency of chromosomal imbalances at -3p, +3q, -4q, +5q, -5q, +7q, and -13q were significantly different between SCC and AC. Subsequently, oncogenetic tree modeling identified different clusters of chromosomal imbalances for SCC and AC. Appearance of the -3p-cluster in SCC was associated with decreased overall survival independent of clinicopathologic parameters (mean, 42.8 +/- 7.5 months vs 80.1 +/- 9.1 months, log rank p = 0.019), whereas in AC no prognostic value could be identified for specific clusters of chromosomal imbalances. Conclusions. Although, the limited number of analyzed cases allows a cautious statement on chromosomal imbalances, the oncogenetic tree modeling suggests distinct patterns of cytogenetic evolution for SCC and AC with implications for clinical outcome in SCC. (Ann Thorac Surg 2011;92:1038-43) (C) 2011 by The Society of Thoracic Surgeons"],["dc.identifier.doi","10.1016/j.athoracsur.2011.04.052"],["dc.identifier.isi","000294247400057"],["dc.identifier.pmid","21871296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22226"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0003-4975"],["dc.title","Prognostic Value of Chromosomal Imbalances in Squamous Cell Carcinoma and Adenocarcinoma of the Lung"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1433"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Annals of Thoracic Surgery"],["dc.bibliographiccitation.lastpage","1439"],["dc.bibliographiccitation.volume","88"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Didilis, Vassilios N."],["dc.contributor.author","Stojanovic, Tomislav"],["dc.contributor.author","Popov, Aron"],["dc.contributor.author","Grossmann, Marius"],["dc.contributor.author","Seipelt, Ralf G."],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.date.accessioned","2018-11-07T11:22:21Z"],["dc.date.available","2018-11-07T11:22:21Z"],["dc.date.issued","2009"],["dc.description.abstract","Background. Emergent coronary artery bypass graft surgery (CABG) for acute myocardial infarction is associated with an increased operative risk. For estimation of mortality risk, the European System for Cardiac Operative Risk Evaluation (EuroSCORE) is appropriate up to a medium risk score (<6 points). To predict mortality risk more accurately in cases of higher EuroSCORE, additional cardiac data can be helpful. Methods. Over a 3-year period, patient data including acute myocardial infarction and emergent CABG were retrospectively reviewed. Univariate and multivariate analysis for in-hospital mortality was performed. The EuroSCORE analysis and follow-up was investigated. Results. Overall in-hospital mortality was 18.3%. Preoperative cardiac related predictors for in-hospital mortality were cardiogenic shock (p < 0.001), very poor left ventricular function (p = 0.001), and ST-segment elevation (p = 0.012). In multivariate regression analysis, age, cardiogenic shock, and pulmonary hypertension were independent preoperative risk factors. According to the EuroSCORE, we could define three statistically different groups: intermediate-risk, high-risk, and very high risk, with an observed mortality of 3.3%, 20.0%, and 63.2%, respectively. The EuroSCORE correlates with but overestimates the mortality risk. In subgroup analysis, the creatine kinase-myocardial band/hour ratio for the intermediate-risk group and ST-segment elevation for the high-risk group were additional cardiac risk factors. Conclusions. Patients with an acute myocardial infarction and emergency aortocoronary CABG have an elevated operative risk. Logistic EuroSCORE overestimates the mortality rate. Three different risk groups can be defined, in which creatine kinase-MB/h-ratio and ST-segment elevation can more accurately predict operative risk. (Ann Thorac Surg 2009;88:1433-9) (C) 2009 by The Society of Thoracic Surgeons"],["dc.identifier.doi","10.1016/j.athoracsur.2009.06.059"],["dc.identifier.isi","000271215700007"],["dc.identifier.pmid","19853087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55978"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0003-4975"],["dc.title","A Three-Group Model to Predict Mortality in Emergent Coronary Artery Bypass Graft Surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]